Related Experiment Videos

[Effectiveness and tolerance of an active combination of timolol and pilocarpine--a pilot project]

K D Schnarr1, H J Merté

  • 1Augenklinik und -poliklinik rechts der Isar der Technischen Universität München.

Klinische Monatsblatter Fur Augenheilkunde
|December 1, 1987
PubMed

Insights

This pilot study explored adding pilocarpine to timolol eyedrops for glaucoma patients. Combination therapy further reduced intraocular pressure, offering a potential new treatment option.

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma is a leading cause of irreversible blindness.
  • Elevated intraocular pressure (IOP) is a primary risk factor for glaucoma progression.
  • Timolol 0.5% is a common treatment for lowering IOP.

Purpose of the Study:

  • To evaluate the efficacy of combination eyedrops in further reducing IOP in glaucoma patients.
  • To compare the effects of timolol with pilocarpine 2% versus timolol with pilocarpine 4%.

Main Methods:

  • A pilot study involving glaucoma patients with IOP around 22 mmHg after timolol treatment.
  • Administration of combination eyedrops: timolol 0.5% with pilocarpine 2% (TP2) or timolol 0.5% with pilocarpine 4% (TP4).
  • Measurement of intraocular pressure at various time points post-administration.

Main Results:

  • TP2 resulted in an additional IOP reduction of 1.9 mmHg at 2 hours and 2.1 mmHg at 6 hours.
  • TP4 showed a greater additional IOP reduction of 3.0 mmHg at 2 hours, 3.5 mmHg at 6 hours, and 2.7 mmHg at 12 hours.
  • Therapeutically relevant IOP lowering duration was 6 hours for TP2 and 12 hours for TP4.

Conclusions:

  • Combination therapy with timolol and pilocarpine eyedrops can achieve further IOP reduction in glaucoma patients.
  • Timolol 0.5% with pilocarpine 4% demonstrated a more pronounced and sustained IOP-lowering effect compared to timolol 0.5% with pilocarpine 2%.

Related Concept Videos